Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
FENNEC PHARMACEUTICALS INC.
Report date August 31, 2026 · Filed September 01, 2026
Section 16 reporting ended · disclosed 2026-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common sharesSEC Table I · non-derivative | Direct | 134,411 |
Reported balance
After 2026-08-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 2,778 · Balance 134,411 F1: Represents shares released from restriction from shares awarded 5/16/2024. |
| Common sharesSEC Table I · non-derivative | Direct | 124,411 |
Reported balance
After 2026-09-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-01 · Sale · Disposed 10,000 · Balance 124,411 F2: Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares released from restriction from shares awarded 5/16/2024.
F2: Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 1, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,000 | $12.11 | $121,100.00 |
DisclosureSEC source: 0001468316-26-000023 · form4-09012026_040901.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,411 F2 · security: Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000023 · form4-09012026_040901.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,411 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,000 | $9.58 | $95,800.00 |
DisclosureSEC source: 0001468316-26-000021 · form4-08042026_040802.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,633 F1 · security: Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000019 · form4-08032026_040804.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,633 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 15,597 | $2.45 Strike: $2.45 | $38,212.65 |
DisclosureSEC source: 0001468316-26-000017 · form4-07022026_040710.xml · derivative · entry 4 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,525,000 Underlying: options · 15,597 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 9,599 | $10.41 | $99,925.59 |
DisclosureSEC source: 0001468316-26-000017 · form4-07022026_040710.xml · nonDerivative · entry 3 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,855 F3 · security: Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 15,597 | $2.45 | $38,212.65 |
DisclosureSEC source: 0001468316-26-000017 · form4-07022026_040710.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000017 · form4-07022026_040710.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Former Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,857 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 15,597 | $2.45 Strike: $2.45 | $38,212.65 |
DisclosureSEC source: 0001468316-26-000015 · form4-06022026_040601.xml · derivative · entry 4 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,556,195 Underlying: options · 15,597 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 9,747 | $9.62 | $93,766.14 |
DisclosureSEC source: 0001468316-26-000015 · form4-06022026_040601.xml · nonDerivative · entry 3 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,079 F3 · security: Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 15,597 | $2.45 | $38,212.65 |
DisclosureSEC source: 0001468316-26-000015 · form4-06022026_040601.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| May 31, 2026 Filed Jun 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000015 · form4-06022026_040601.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,229 F1 · security: Represents shares released from restriction from shares awarded 5/16/2024. Read SEC document |
| May 01, 2026 Filed May 1, 2026 21:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 15,598 | $2.45 Strike: $2.45 | $38,215.10 |
DisclosureSEC source: 0001468316-26-000013 · form4-05012026_090522.xml · derivative · entry 4 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,571,792 Underlying: options · 15,598 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| May 01, 2026 Filed May 1, 2026 21:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,781 | $6.47 | $69,753.07 |
DisclosureSEC source: 0001468316-26-000013 · form4-05012026_090522.xml · nonDerivative · entry 3 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,451 F3 · security: Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| May 01, 2026 Filed May 1, 2026 21:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 15,598 | $2.45 | $38,215.10 |
DisclosureSEC source: 0001468316-26-000013 · form4-05012026_090522.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| April 30, 2026 Filed May 1, 2026 21:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000013 · form4-05012026_090522.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares released from restriction from shares awarded 5/16/2024. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 15,598 | $2.45 Strike: $2.45 | $38,215.10 |
DisclosureSEC source: 0001468316-26-000010 · form4-04022026_040403.xml · derivative · entry 4 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,587,390 Underlying: options · 15,598 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,946 | $6.31 | $69,069.26 |
DisclosureSEC source: 0001468316-26-000010 · form4-04022026_040403.xml · nonDerivative · entry 3 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,856 F3 · security: Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025.. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 15,598 | $2.45 | $38,215.10 |
DisclosureSEC source: 0001468316-26-000010 · form4-04022026_040403.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000010 · form4-04022026_040403.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,204 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 15,598 | $2.45 Strike: $2.45 | $38,215.10 |
DisclosureSEC source: 0001468316-26-000008 · form4-03032026_040301.xml · derivative · entry 4 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,587,390 Underlying: options · 15,598 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,079 | $8.36 | $84,260.44 |
DisclosureSEC source: 0001468316-26-000008 · form4-03032026_040301.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,996 F2 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 15,598 | $2.45 | $38,215.10 |
DisclosureSEC source: 0001468316-26-000008 · form4-03032026_040301.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000008 · form4-03032026_040301.xml · nonDerivative · entry 3 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,204 F3 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 21:54 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 15,598 | $2.45 Strike: $2.45 | $38,215.10 |
DisclosureSEC source: 0001468316-26-000006 · form4-02022026_090248.xml · derivative · entry 3 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,602,988 Underlying: options · 15,598 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 21:54 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,349 | $7.76 | $80,308.24 |
DisclosureSEC source: 0001468316-26-000006 · form4-02022026_090248.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,477 F2 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 21:54 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 15,598 | $2.45 | $38,215.10 |
DisclosureSEC source: 0001468316-26-000006 · form4-02022026_090248.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000004 · form4-02022026_040203.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,228 F1 · security: 1. Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 15,598 | $2.45 Strike: $2.45 | $38,215.10 |
DisclosureSEC source: 0001468316-26-000002 · form4-01052026_040101.xml · derivative · entry 4 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,618,586 Underlying: Options · 15,598 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,312 | $7.60 | $78,371.20 |
DisclosureSEC source: 0001468316-26-000002 · form4-01052026_040101.xml · nonDerivative · entry 3 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,020 F3 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 15,598 | $2.45 | $38,215.10 |
DisclosureSEC source: 0001468316-26-000002 · form4-01052026_040101.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-26-000002 · form4-01052026_040101.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,734 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 23:41 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,000 | $7.54 | $75,400.00 |
DisclosureSEC source: 0001468316-25-000016 · form4-12052025_111200.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,526 F1 · security: Represents shares sold pursuant to a 10b5-1 plan dated August 23, 2024. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 23:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-25-000014 · form4-12022025_061201.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,526 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 21:10 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,000 | $8.10 | $81,000.00 |
DisclosureSEC source: 0001468316-25-000013 · form4-11062025_041103.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,318 F1 · security: Represents shares sold pursuant to a 10b5-1 plan dated August 23, 2024. Read SEC document |
| October 31, 2025 Filed Nov 3, 2025 22:33 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-25-000011 · form4-11032025_101146.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,318 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| October 08, 2025 Filed Oct 8, 2025 21:08 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 4,609 | $2.45 Strike: $2.45 | $11,292.05 |
DisclosureSEC source: 0001468316-25-000009 · form4-10082025_091025.xml · derivative · entry 2 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,634,184 Underlying: options · 4,609 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026. Read SEC document |
| October 08, 2025 Filed Oct 8, 2025 21:08 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 4,609 | $2.45 | $11,292.05 |
DisclosureSEC source: 0001468316-25-000009 · form4-10082025_091025.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026. Read SEC document |
| October 06, 2025 Filed Oct 6, 2025 22:22 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,000 | $9.78 | $97,800.00 |
DisclosureSEC source: 0001468316-25-000007 · form4-10062025_101039.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,501 F1 · security: Represents shares sold pursuant to a 10b5-1 plan dated August 23, 2024. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 20:10 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001468316-25-000005 · form4-10012025_041002.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,501 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Options · Derivative | 36,207 | $2.45 Strike: $2.45 | $88,707.15 |
DisclosureSEC source: 0001415889-25-023897 · form4-09082025_100947.xml · derivative · entry 2 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,638,793 Underlying: options · 36,207 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 36,207 | $2.45 | $88,707.15 |
DisclosureSEC source: 0001415889-25-023897 · form4-09082025_100947.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026. Read SEC document |
| September 04, 2025 Filed Sep 4, 2025 20:10 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,000 | $8.92 | $89,200.00 |
DisclosureSEC source: 0001415889-25-023647 · form4-09042025_040901.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,086 F1 · security: Represents shares sold pursuant to a 10b5-1 plan dated August 23, 2024. Read SEC document |
| August 31, 2025 Filed Sep 2, 2025 20:10 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023395 · form4-09022025_040901.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,086 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| August 05, 2025 Filed Aug 5, 2025 21:33 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,000 | $8.09 | $80,900.00 |
DisclosureSEC source: 0001415889-25-021068 · form4-08052025_090820.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,878 F1 · security: Represents shares sold pursuant to a 10b5-1 plan dated August 23, 2024. Read SEC document |
| July 31, 2025 Filed Aug 1, 2025 20:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020850 · form4-08012025_040802.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,878 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| July 03, 2025 Filed Jul 7, 2025 20:30 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,000 | $8.61 | $86,100.00 |
DisclosureSEC source: 0001415889-25-019414 · form4-07072025_040701.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,670 F1 · security: Represents shares sold pursuant to a 10b5-1 plan dated August 23, 2024. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 22:57 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-018800 · form4-07012025_100737.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,670 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,000 | $7.78 | $77,800.00 |
DisclosureSEC source: 0001415889-25-015988 · form4-06062025_040601.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,462 F1 · security: Represents shares sold pursuant to a 10b5-1 plan dated August 23, 2024. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 21:02 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015218 · form4-06022025_090638.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,462 F1 · security: Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.